Table 3.
Effects of KMUP-1 on monocrotaline-induced changes in MABP, HR, MPAP, RV/LV + S ratio and PA wall thickness
| Treatment | MABP (mmHg) | HR (bpm) | MPAP (mmHg) | RV/LV+S (%) | Wall thickness (%) |
|---|---|---|---|---|---|
| Control | 114.5 ± 6.4 | 365 ± 20 | 12.3 ± 1.2 | 21.4 ± 0.4 | 26.9 ± 2.7 |
| Monocrotaline | 102.5 ± 8.2 | 344 ± 18 | 30.7 ± 1.2## | 44.8 ± 1.0## | 59.9 ± 12.7# |
| KMUP-1 | |||||
| 5 mg·kg−1, p.o. | 104.4 ± 5.4 | 342 ± 12 | 21.8 ± 2.9* | 31.5 ± 0.7* | 30.7 ± 8.6* |
| 1 mg·kg−1, i.p. | 100.2 ± 4.0 | 384 ± 17 | 18.7 ± 4.6* | 35.8 ± 1.0* | 40.8 ± 3.5* |
Data in the table are means ± s.e. of n= 6.
*
P < 0.05 versus monocrotaline;
#
P < 0.05,
##
P < 0.01 versus control.
Twenty-one days after monocrotaline injection (i.p.), rats were anaesthetized; MABP, HR and MPAP were measured and then samples were taken for analysis. KMUP-1 or vehicle was given daily for 21 days after monocrotaline.
HR, heart rate; MABP, mean arterial blood pressure; MPAP, mean pulmonary artery pressure; PA, pulmonary artery; RV/LV + S, weight ratio of right ventricular wall area to left ventricular wall area plus septum.